Syndax Pharmaceuticals, Inc.
SNDX
$10.99
$0.292.71%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.72M | 23.68M | 16.00M | 3.50M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.72M | 23.68M | 16.00M | 3.50M | -- |
| Cost of Revenue | 186.87M | 185.98M | 174.75M | 142.87M | 128.98M |
| Gross Profit | -143.14M | -162.30M | -158.75M | -139.37M | -128.98M |
| SG&A Expenses | 138.89M | 120.88M | 105.97M | 92.13M | 77.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 387.39M | 363.35M | 337.21M | 291.49M | 263.45M |
| Operating Income | -343.67M | -339.67M | -321.21M | -287.99M | -263.45M |
| Income Before Tax | -331.20M | -318.76M | -297.06M | -264.08M | -240.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -331.20 | -318.76 | -297.06 | -264.08 | -240.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -331.20M | -318.76M | -297.06M | -264.08M | -240.63M |
| EBIT | -343.67M | -339.67M | -321.21M | -287.99M | -263.45M |
| EBITDA | -343.66M | -339.66M | -321.20M | -287.98M | -263.44M |
| EPS Basic | -3.87 | -3.73 | -3.63 | -3.38 | -3.22 |
| Normalized Basic EPS | -2.42 | -2.33 | -2.27 | -2.11 | -2.01 |
| EPS Diluted | -3.87 | -3.73 | -3.64 | -3.38 | -3.23 |
| Normalized Diluted EPS | -2.42 | -2.33 | -2.27 | -2.11 | -2.01 |
| Average Basic Shares Outstanding | 342.67M | 341.71M | 328.44M | 312.86M | 297.23M |
| Average Diluted Shares Outstanding | 342.67M | 341.71M | 328.44M | 312.86M | 297.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |